Behandling av T-prolymfocyttleukemi med monoklonalt anti-CD52-antistoff (alemtuzumab)
Engelsk titel: Treatment of T-cell prolympholytic leukemia with monoclonal anti-CD52 antibody (alemtuzumab)
Läs online
Författare:
Flöisand Y
;
Brinch L
;
Gedde-Dahl T
;
Tjönnfjord GE
Email: yngvar.floisand@rikshospitalet.no
Språk: Nor
Antal referenser: 14
Dokumenttyp:
Artikel
UI-nummer: 04041891
Sammanfattning
RESULTS AND INTERPRETATION : Four of our patients were treated with alemtuzumab. Three showed complete or partial response. One patient underwent allogeneic stem cell transplantation with an HLA-identical sibling, but died on day 21 as a result of transplantation complications. The treatment is generally well tolerated; the principal management problem is immunosuppression, as shown in one patient who developed a varicella-zoster meningoencephalomyelitis as a consequence of not receiving antiviral prophylaxis. The main infusion-related adverse effects are fever and chills.
MATERIALS AND METHODS : Five patients treated at Rikshospitalet University Hospital are evaluated and the literature on T-PLL is reviewed.
INTRODUCTION : T-cell prolymphocytic leukaemia (T-PLL) is a rare post-thymic T-cell malignancy with an aggressive clinical course. It has generally been resistant to alkylating chemotherapy, but some effect has been observed with the purine analog 2-deoxycoformicin with documented partial or complete response rates in up to 45% of patients. Treatment with monoclonal antibodies against CD 52 has been shown to be highly effective in T-PLL with response rates of up to 76%. This may allow for further consolidating treatment with high-dose chemotherapy with autologous stem cell support or allogeneic stem cell transplantation.